CompletedNot Applicable

Gene Modulation of NLRP3, IL-1β and TNF-α in Peripheral Blood of Patients With Exogenous Obesity Treated With Berberine

120 participantsStarted 2019-01-05

Plain-language summary

The patients will be invited to participate in a research study aimed at determining the Gene Modulation of NLRP3, IL-1β and TNFα in peripheral blood of patients with exogenous obesity treated with berberine.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * • Patients with BMI ≥ 30kg/m2 * With risk factors for type 2 diabetes (history of diabetic parents or siblings, sedentary habits) * Fasting blood glucose ≤ 126 mg/dL or glycosylated hemoglobin \< 6.5% * Controlled arterial hypertension * \>18 years of age * Accept and sign the informed consent Exclusion Criteria: * • Pregnancy patients * Diabetics patients * Presenting any serious adverse effect * Patients who decide to withdraw from the protocol

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

To determine the effects of Berberine on the gene modulation of NLRP3, in peripheral blood of patients with exogenous obesity

Timeframe: From enrollment to the end of treatment at 3 months

To determine the effects of Berberine on the gene modulation of IL-1β in peripheral blood of patients with exogenous obesity

Timeframe: "From enrollment to the end of treatment at 3 months

To determine the effects of Berberine on the gene modulation of TNFα in peripheral blood of patients with exogenous obesity

Timeframe: From enrollment to the end of treatment at 3 months

Trial details

NCT IDNCT06703086

SponsorNational Polytechnic Institute, Mexico

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-08-15

View on ClinicalTrials.gov More Obesity trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

To determine the effects of Berberine on the gene modulation of NLRP3, in peripheral blood of patients with exogenous obesity

Timeframe: From enrollment to the end of treatment at 3 months

To determine the effects of Berberine on the gene modulation of IL-1β in peripheral blood of patients with exogenous obesity

Timeframe: "From enrollment to the end of treatment at 3 months

To determine the effects of Berberine on the gene modulation of TNFα in peripheral blood of patients with exogenous obesity

Timeframe: From enrollment to the end of treatment at 3 months